oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes Abstract 4367751: of High Risk Patients: A Systematic Review Meta-Analysis VisualAbstract: Semaglutide Improves Outcomes in
Description
Gonzlez-Lpez MA, Vilanova I, Ocejo-Vials G, Arlegui R, Navarro I, Guiral S, et al
Possible experiences: mild fullness after large meals, occasional subtle nausea, no measurable weight change
With nearly nine in 10 Americans now aware of these weight loss drugs, the 12.4% of U.S
however, this hasnt been demonstrated in humans
Enter GLP-1 agonists, the unsung heroes initially designed to manage Type 2 diabetes and aid weight loss but now showing promising effects in controlling impulses
Studies have shown that SGLT-2 inhibitors can induce weight loss of 2%-3% and may lead to improvement of hepatic steatosis and fibrosis [139,140]
